132
Novartis will invest equal amounts of €250 million ($272 million) at its locations in Kundl and Schaftenau to advance the continuous supply of biopharmaceuticals from Austria and adhere to the company’s strategy of expanding its cell culture technology.
“Innovative biopharmaceuticals are posing new opportunities in medicine where classical drugs and therapies have come to their limitations,” a spokesperson for Novartis told BioProcess Insider.
“They open new therapeutic options for a variety of oncological, cardiovascular, and…